BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » News » Publication » ApoCIII links islet insulin resistance to beta cell failure in diabetes

ApoCIII links islet insulin resistance to beta cell failure in diabetes

Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes

In a study published in the May 2015 issue of PNAS, it was demonstrated that apolipoprotein CIII (apoCIII) can serve as a link between insulin resistance and β-cell failure in type 2 diabetes mellitus. Preventing insulin resistance at the islet level is thus crucial to preserve β-cell mass, especially during the late phase of T2DM, where β cells are progressively lost. If results are confirmed in human islets from T2DM patients, local islet production of apoCIII may become a drugable target and thereby form the basis for a novel diabetes treatment regimen. It is of interest to note that there are human data from subjects with a genetic mutation in the apoCIII gene and thereby life-long reduced levels of apoCIII, demonstrating that these persons are overall healthier and have increased insulin sensitivity.

Read more:    Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes. Karin Åvall, Yusuf Ali, Ingo B. Leibiger, Barbara Leibiger, Tilo Moede, Meike Paschen, Andrea Dicker, Elisabetta Daré, Martin Köhler, Erwin Ilegems, Midhat H. Abdulreda, Mark Graham, Rosanne M. Crooke, Vanessa S. Y. Tay, Essam Refai, Stefan K. Nilsson, Stefan Jacob, Lars Selander, Per-Olof Berggren and Lisa Juntti-Berggren. PNAS, USA 2015 May 19; 112(20):E2611-2619. Doi: 10.1073/pnas. 1423849112

September 2, 2020 Catharina Rahm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications February 6, 2025
  • Årsstämma 17 juni 2024
    Årsstämma 17 juni 2024 June 2, 2024
  • Researchers use the eye as a window to study liver health
    Researchers use the eye as a window to study liver health February 8, 2024
  • ERC Proof of Concept to Professor Per-Olof Berggren
    ERC Proof of Concept to Professor Per-Olof Berggren February 7, 2024
  • The anterior chamber of the eye as a servant to medical research in translation
    The anterior chamber of the eye as a servant to medical research in translation February 7, 2024
  • Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize
    Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize February 7, 2024
  • Eye implant may be used to treat diabetes
    Eye implant may be used to treat diabetes February 7, 2024
  • Årsstämma 16 juni 2023
    Årsstämma 16 juni 2023 May 29, 2023
  • New strategy to preserve insulin-producing cells in diabetes
    New strategy to preserve insulin-producing cells in diabetes August 19, 2022
  • Kallelse till årsstämma 27 juni 2022
    Kallelse till årsstämma 27 juni 2022 June 6, 2022

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved